1PB AbbVie || AbbVie

Partnershipsthat makea difference

32 AbbVie || AbbVie

Together, we aim to solve the world’s greatest health challenges.

Together, we aim to solve the world’s greatest health challenges. It takes desire

and determination to find a new way forward. And no one gets there alone.

Uniting the best of pharma and the boldness of biotech, we’re going beyond

conventional thinking to make a real difference. Starting with science, we arrive

at solutions that help millions of patients around the world live better.

It Takes All of Us

$32.7 Billion2018 revenue

22Number of primary research and manufacturing facilities around the world

30,000+Approximate number of employees worldwide

175+Number of countries where products are sold

30 MillionPatients treated globally with AbbVie’s medicines

54 AbbVie || AbbVie

With a 125-year history of achieve ment as part

of Abbott, we apply this strength to new and

unsolved problems as AbbVie.

We are a proven biopharmaceutical leader. We

take on the toughest health care challenges.

What results is something rare today: a global

biopharmaceutical company that discovers

and advances innovative therapies to meet

pressing health needs around the globe. We’re

using the power of our past—and the promise

of our present—to improve lives for patients,

their families and communities.

Taking on the toughest health care challenges

Corporate HeadquartersNorth Chicago, Illinois, USA

ABBVNYSE listing

Business Development

& Acquisitions

Alliance Management

AbbVie Ventures

Therapy Areas and Functions

R&D

Global Commercial Development

Commercial

Corporate Strategy Office

(CSO)

An integrated approach to external innovation

Search & Evaluation

Technology Licensing &

Collaborations

R&D Ops

76 AbbVie || AbbVie

At AbbVie, we partner to achieve two important outcomes: to deliver innovative medicines and to make a remarkable impact on people’s lives.

We start with a highly integrated approach to developing and sustaining our partnerships. In our approach to external innovation, we work as one connected unit with a commitment to establishing collaborations across the development continuum.

Our goal is to create long-term mutually beneficial relationships. With a shared vision as our foundation, we align our collective capabilities in service of a joint mission to conduct groundbreaking science and bring innovative medicines to societies around the globe.

As we progress, we make sure that everyone from working teams through senior leadership is aware of and invested in nurturing the assets we develop together.

From start to finish, we manage for success—from early identification and mitigation of risks to shared accountability and reward for successful outcomes.

Our Unique Approach How We Work Together

Search and EvaluationFocused on identifying and evaluating new opportunities that complement and enhance our existing internal innovation strategies. S&E works in close partnership with our R&D and commercial teams, BD&A and Ventures to thoughtfully address each opportunity.

Business Development and AcquisitionsEvaluates a variety of partnership structures to meet the needs of both parties. BD&A works closely with S&E, and our commercial and R&D organizations to evaluate new opportunities.

Alliance ManagementHighly successful partnerships result from an ongoing commitment to realize a shared vision. At AbbVie, we have a dedicated team that is involved in all aspects of the partnership from contracting through commercialization to ensure positive outcomes for all parties.

AbbVie VenturesWe strategically invest in transformational scientific opportunities to augment our core R&D interests and gain access to next-generation science and proven scientific leaders. Our expertise in drug development and commercialization can be a valuable resource to even the earliest stage companies.

At AbbVie, we partner to achieve two important outcomes: to deliver innovative medicines and to make a remarkable impact on people’s lives.

98 AbbVie || AbbVie

As leading experts in autoimmune diseases and therapies, AbbVie is focused on developing new medicines to address chronic progressive diseases in the field of immunology. Our programs focus on investigating both targeted oral therapies and biologics.

IMMUNOLOGY

We discover and develop new drugs in therapeutic areas that we believe will make the most significant impact on the disease and its management.

Our current innovative research focuses on developing therapies for neurodegenerative diseases by targeting mechanisms that prevent neurodegeneration and promote neuroprotection. We are interested in drug targets, early and late stage assets, biomarkers and technologies. For assets, we prioritize first-in-class, or those that are clearly differentiated as superior vs. existing and emerging therapies.

Areas of interest:– Alzheimer’s disease– Parkinson’s disease– Other neurodegenerative

diseases that share proteinopathy mechanisms with AD and PD such as tauopathies, synucleinopathies and TDP43

– Multiple sclerosis

Our research is committed to discovering and developing targeted therapies that work against the processes cancer cells need to survive. We are investigating both small and large molecule approaches, as well as novel modalities, and our internal research efforts are balanced with external collaborations across industry, academia and healthcare.

Immunology Neurology

Oncology

External Innovation: Therapeutic Areas of Focus

Biologics Platforms– Technologies for the discovery, engineering

and optimization of protein therapeutics– Innovative technologies for drug delivery and

distribution– Next-generation protein therapeutics

technologies

Medicinal Chemistry & Platform Chemistry Technologies

– Innovative technologies for drug discovery and development

– Best-in-class innovative synthesis strategies and molecules

Additional Focus Areas

Areas of interest:

– Gastroenterology (Crohn’s disease, ulcerative colitis)

– Dermatology (psoriasis, atopic dermatitis)

– Rheumatology (RA, PsA, SpA)– Novel therapies for interferon

and TH2 driven diseases (SLE, systemic sclerosis, Sjögren’s syndrome)

– Fibrotic conditions associated with certain inflammatory conditions

Areas of interest:

– Solid tumors and hematologic malignancies

– Targeted therapies for • Regulated cell death • B-cell signaling • Immuno-oncology

– Next generations of targeted small molecules (including technologies to enable targeting of hard-to-drug proteins)

– Novel targeted biologics– New T-cell-engaging- and T-cell

receptor-based approaches

Target Enabling Science and Technology– New genomic & proteomic profiling

technologies– Novel technology for functionalizing the

genome– State-of-the-art data analysis methodology– Innovative small molecule screening and

assay technology– Cutting-edge methods in protein sciences

1110 AbbVie || AbbVie

Latin AmericaBarceloneta, PR

Jayuya, PR

Latin AmericaRegional HQ:

North Chicago, IL

United StatesNorth Chicago, IL

Lake County, ILCambridge, MAWorcester, MAWyandotte, MISunnyvale, CA

Redwood City, CASouth San Francisco, CA

JAPACTokyo, JP

Singapore, SG

EEME&ARegional HQ:

Paris, FR

Partnering with AbbVie means tapping into a unique combination of strengths. As an established company, we bring the discipline, capabilities and resources that are needed to develop and deliver solutions around the world.

United StatesRegional HQ:

North Chicago, IL

EuropeLudwigshafen, DE

Cork, IEBallytivnan, IE

Sligo, IECampoverde, IT

Western Europe & Canada

Regional HQ: Paris, FR

JAPACRegional HQ:

Singapore, SG

AbbVie’s Global Reach

1312 AbbVie || AbbVie

Collaborations are critical, not just to the success of our company, but to the success of our industry.

We partner and collaborate with peer companies, universities, patient advocacy groups and others to help find solutions for patients. We are interested in a variety of collaborations including venture investing, co-development partnerships for discovery through late-stage opportunities, licensing and acquisitions.

We look forward to the opportunity to get to know you and for you to get to know AbbVie.

Our award-winning team of professionals is ready to meet with you to share our

capabilities and discuss your business opportunities. Together, we can collaborate to have a remarkable impact on patients’ lives around the world.

The following page contains information on how to get in touch with us. We invite you to share your ideas and come meet with us.

Thank you, and we look forward to hearing from you.

As you weigh the many partnership opportunities available to you, consider what you aim to achieve.

Our passion is translating science into effective medicine for the good of patients. Together with our partners, AbbVie shares a commitment to address the world’s greatest health needs.

AbbVie is dedicated to carefully evaluating every opportunity presented to us, and our licensing professionals thoughtfully manage each inquiry we receive.

AbbVie Ventures

Email abbvieventures@abbvie.com

Web http://ventures.abbvie.com/

Business Development & Acquisitions

Email partnerships@abbvie.com

Web www.abbvie.com

Mail AbbVie 1 North Waukegan Road North Chicago, IL 60064 USA

We Invite You to Contact Us

Collaborations are critical, not just to the success of our company, but to the success of our industry.

1514 AbbVie || AbbVie

Notes

AbbVie 1 North Waukegan Road North Chicago, IL 60064 U.S.A.

abbvie.comBSG-100070ALL-ABBV-190266Copyright ©2019 AbbVie. All rights reserved.